Mohamed Wa'El Ahmed Hashad Longeveron Inc. (LGVN) insider trading activity

Mohamed Wa'El Ahmed Hashad is Chief Executive Officer of Longeveron Inc.. Currently has a direct ownership of 278,261 shares of LGVN, which is worth approximately $581,565. The most recent transaction as insider was on Oct 01, 2024, when has been sold 13,357 shares (Class A Common Stock) at a price of $1.88 per share, resulting in proceeds of $25,111. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 278K

1318.54% 3M change

485.0% 12M change

Total Value Held $581,565

Mohamed Wa'el Ahmed Hashad Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 01 2024	SELL Payment of exercise price or tax liability	$25,111 $1.88 p/Share	13,357 Reduced 4.58%	278,261 Class A Common Stock
Aug 15 2024	SELL Payment of exercise price or tax liability	$96,550 $2.46 p/Share	39,248 Reduced 30.28%	90,368 Class A Common Stock
Aug 15 2024	BUY Grant, award, or other acquisition	-	311,250 Added 48.47%	330,866 Class A Common Stock
Apr 11 2024	BUY Open market or private purchase	$24,999 $2.35 p/Share	10,638 Added 35.16%	19,616 Class A Common Stock
Mar 12 2024	SELL Payment of exercise price or tax liability	$17,747 $0.54 p/Share	32,866 Reduced 26.8%	89,777 Common Stock, par valu...
Mar 12 2024	BUY Grant, award, or other acquisition	-	80,200 Added 39.54%	122,643 Common Stock, par valu...
Jan 02 2024	SELL Payment of exercise price or tax liability	$6,762 $1.32 p/Share	5,123 Reduced 10.77%	42,443 Common Stock
Sep 12 2023	BUY Exercise of conversion of derivative security	$30,000 $3.0 p/Share	10,000 Added 17.37%	47,566 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$11,412 $2.64 p/Share	4,323 Reduced 10.32%	37,566 Common Stock
Aug 18 2023	SELL Payment of exercise price or tax liability	$13,949 $3.25 p/Share	4,292 Reduced 9.29%	41,889 Common Stock
Apr 05 2023	SELL Payment of exercise price or tax liability	$9,967 $2.61 p/Share	3,819 Reduced 7.64%	46,181 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	50,000 Added 50.0%	50,000 Common Stock

Also insider at

AKTX

Akari Therapeutics Plc Healthcare

MWA